A Phase 1 interventional study of Poliorix in Poliomyelitis, sponsored by GlaxoSmithKline. Completed at 1 site in China. Open to participants aged 60 Days to 90 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-17.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis — 3 open to participants now, 3 under way, none of them phase 3. Poliovirus Vaccine, Inactivated · Poliomyelitis.
Among the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis, this one is the 17th largest by enrollment, is one of 2 that started in 2009, is one of 2 in phase 1, and was the 1st registered.
275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.
Browse Poliomyelitis studies →3 of the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis are open now, in 1 country. Recruiting first, the newest first:
Sinovac Biotech Co., Ltd · Sites in China
Ages 3 mo–50 yrs · Healthy volunteers
Institute of Medical Biology, Chinese Academy of Medical Sciences · Sites in China
Ages 2 mo–2 mo · Healthy volunteers
International Centre for Diarrhoeal Disease Research, Bangladesh
Ages 42 days–48 days · Healthy volunteers
By country, each count listing its studies:
Poliovirus Vaccine, Inactivated: first FDA approval 2002 (Pediarix). What it is approved for, and how studies give it, is on its page →
Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 60 Days to 90 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 4 · Phase 4 11
First in 2009; this study’s year is marked. 2 started in 2009.
This study's enrollment of 25 is below the median of 478 across 250 interventional studies indexed under Poliomyelitis.
Median enrollment 672 across the 18 interventional studies. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 18 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Poliomyelitis by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 43 finished, 30 (70%) have results posted.
Among the 44 studies in Poliomyelitis by GlaxoSmithKline, this one is the 39th largest by enrollment of the 41 interventional ones that give a count, is one of 7 that started in 2009, is the only one in phase 1, and was the 19th registered.
GlaxoSmithKline’s Poliomyelitis studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 44 in Poliomyelitis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the safety and reactogenicity of Poliorix given as primary vaccination course to Chinese children at 2, 3 and 4 months of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male or female subjects between, and including, 60 and 90 days of age at the time of the first vaccination, receive 3 doses of Poliorix at 2 (Study Day 0, Visit 1), 3 (Study Month 1, Visit 2) and 4 (Study Month 2, Visit 3) months of age, administered intramuscularly into the upper right side of the thigh.
Biological: Poliorix
All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.
Number of Subjects Reporting Solicited Local Symptoms
Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of the symptom irrespective of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimetres (mm) of injection site.
Time frame: During the 4-day follow-up period after each dose of study vaccine.
Number of Subjects Reporting Solicited General Symptoms
Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever \[defined as axillary temperature equal to or above (≥) 37.1 degrees Celsius (°C)\]. Any = occurrence of symptom regardless of intensity grade of relationship to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = subject did not eat at all. Grade 3 fever = fever above (\>) 39.0°C. Related = symptom assessed by the investigator as related to vaccination.
Time frame: During the 4-day follow-up period after each dose of study vaccine.
Number of Subjects Reporting Unsolicited Adverse Events (AEs)
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.
Time frame: During the 31-days follow-up period after each dose of the study vaccine.
Number of Subjects Reporting Serious Adverse Events (SAEs)
SAEs assessed included any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: During the entire study period (from Dose 1 up to one month following last vaccine dose).
| Milestone | IPV Group |
|---|---|
| Started | 25 |
| Completed | 23 |
| Not completed | 2 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 1 |
Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of the symptom irrespective of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimetres (mm) of injection site.
| Participants | IPV Group |
|---|---|
| Any Pain, Dose 1 | 1 |
| Grade 3 Pain, Dose 1 | 0 |
| Any Redness, Dose 1 | 2 |
| Grade 3 Redness, Dose 1 | 0 |
| Any Swelling, Dose 1 | 1 |
| Grade 3 Swelling, Dose 1 | 0 |
| Any Pain, Dose 2 | 2 |
| Grade 3 Pain, Dose 2 | 0 |
| Any Redness, Dose 2 | 1 |
| Grade 3 Redness, Dose 2 | 0 |
| Any Swelling, Dose 2 | 1 |
| Grade 3 Swelling, Dose 2 | 0 |
| Any Pain, Dose 3 | 1 |
| Grade 3 Pain, Dose 3 | 0 |
| Any Redness, Dose 3 | 0 |
| Grade 3 Redness, Dose 3 | 0 |
| Any Swelling, Dose 3 | 0 |
| Grade 3 Swelling, Dose 3 | 0 |
| Any Pain, Across doses | 3 |
| Grade 3 Pain, Across doses | 0 |
| Any Redness, Across doses | 2 |
| Grade 3 Redness, Across doses | 0 |
| Any Swelling, Across doses | 2 |
| Grade 3 Swelling, Across doses | 0 |
Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever \[defined as axillary temperature equal to or above (≥) 37.1 degrees Celsius (°C)\]. Any = occurrence of symptom regardless of intensity grade of relationship to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = subject did not eat at all. Grade 3 fever = fever above (\>) 39.0°C. Related = symptom assessed by the investigator as related to vaccination.
| Participants | IPV Group |
|---|---|
| Any Drowsiness, Dose 1 | 7 |
| Grade 3 Drowsiness, Dose 1 | 0 |
| Related Drowsiness, Dose 1 | 7 |
| Any Irritability, Dose 1 | 10 |
| Grade 3 Irritability, Dose 1 | 0 |
| Related Irritability, Dose 1 | 10 |
| Any Loss of appetite, Dose 1 | 7 |
| Grade 3 Loss of appetite, Dose 1 | 0 |
| Related Loss of appetite, Dose 1 | 7 |
| Any Fever, Dose 1 | 8 |
| Grade 3 Fever, Dose 1 | 0 |
| Related Fever, Dose 1 | 6 |
| Any Drowsiness, Dose 2 | 2 |
| Grade 3 Drowsiness, Dose 2 | 0 |
| Related Drowsiness, Dose 2 | 2 |
| Any Irritability, Dose 2 | 7 |
| Grade 3 Irritability, Dose 2 | 0 |
| Related Irritability, Dose 2 | 6 |
| Any Loss of appetite, Dose 2 | 4 |
| Grade 3 Loss of appetite, Dose 2 | 0 |
| Related Loss of appetite, Dose 2 | 3 |
| Any Fever, Dose 2 | 3 |
| Grade 3 Fever, Dose 2 | 0 |
| Related Fever, Dose 2 | 3 |
| Any Drowsiness, Dose 3 | 3 |
| Grade 3 Drowsiness, Dose 3 | 0 |
| Related Drowsiness, Dose 3 | 1 |
| Any Irritability, Dose 3 | 7 |
| Grade 3 Irritability, Dose 3 | 2 |
| Related Irritability, Dose 3 | 3 |
| Any Loss of appetite, Dose 3 | 6 |
| Grade 3 Loss of appetite, Dose 3 | 0 |
| Related Loss of appetite, Dose 3 | 3 |
| Any Fever, Dose 3 | 4 |
| Grade 3 Fever, Dose 3 | 0 |
| Related Fever, Dose 3 | 2 |
| Any Drowsiness, Across doses | 8 |
| Grade 3 Drowsiness, Across doses | 0 |
| Related Drowsiness, Across doses | 8 |
| Any Irritability, Across doses | 14 |
| Grade 3 Irritability, Across doses | 2 |
| Related Irritability, Across doses | 12 |
| Any Loss of appetite, Across doses | 9 |
| Grade 3 Loss of appetite, Across doses | 0 |
| Related Loss of appetite, Across doses | 8 |
| Any Fever, Across doses | 12 |
| Grade 3 Fever, Across doses | 0 |
| Related Fever, Across doses | 9 |
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.
| Participants | IPV Group |
|---|---|
| Number of Subjects Reporting Unsolicited Adverse Events (AEs) | 15 |
SAEs assessed included any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject.
| Participants | IPV Group |
|---|---|
| Number of Subjects Reporting Serious Adverse Events (SAEs) | 0 |
Collected over Solicited symptoms: during the 4-day post-vaccination period after each vaccine dose. Unsolicited AEs: during the 31-day post-vaccination period after each vaccine dose. SAEs: during the entire study period (from Dose 1 up to one month following last vaccine dose).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IPV Group | 0/25 (0%) | 0/25 (0%) | 20/25 (80%) |
| Event | IPV Group |
|---|---|
| PyrexiaGeneral disorders | 16/25 |
| IrritabilityPsychiatric disorders | 14/25 |
| Decreased appetiteMetabolism and nutrition disorders | 9/25 |
| SomnolenceNervous system disorders | 8/25 |
| Upper respiratory tract infectionInfections and infestations | 7/25 |
| DiarrhoeaGastrointestinal disorders | 5/25 |
| NasopharyngitisInfections and infestations | 4/25 |
| DyspepsiaGastrointestinal disorders | 3/25 |
| PainGeneral disorders | 3/25 |
| ErythemaSkin and subcutaneous tissue disorders | 2/25 |
| Age, Continuous(Weeks) | IPV Group |
|---|---|
| Mean | 9.6 ± 1.38 |
| Sex: Female, Male(Participants) | IPV Group |
|---|---|
| Female | 15 |
| Male | 10 |
| Race/Ethnicity, Customized(Participants) | IPV Group |
|---|---|
| Asian-Chinese Heritage | 25 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Aug 2009 to primary completion in Nov 2009, 3 months.
Results were first posted in Dec 2018, 9 years 1 month after primary completion.
Of 12 phase 1 interventional studies under Poliomyelitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 3 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Poliovirus Vaccine, Inactivated